BTLA/B-andT-lymphocyte attenuator/CD272 (Fc fusion)
Recombinant Human B- and T-Lymphocyte Attenuator is produced by our Mammalian expression system and the target gene encoding Lys31-Leu150 is expressed with a Fc tag at the C-terminus.
Product Specifications
Background
B- and T-Lymphocyte Attenuator (BTLA) is a single-pass type I membrane protein containing 1 Ig-like V-type (immunoglobulin-like) domain. BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4. However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a lymphocyte inhibitory receptor that inhibits lymphocytes during immune response. BTLA also is a ligand for tumor necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM) . BTLA-HVEM complexes negatively regulate T-cell immune responses.
Synonyms
B- and T-Lymphocyte Attenuator; B- and T-Lymphocyte-Associated Protein; CD272; BTLA
Expression System
Human cells
Endotoxin
Less than 0.1 ng/ µg (1 IEU/ µg) as determined by LAL test.
Purity
Greater than 95% as determined by reducing SDS-PAGE.
Form
Lyophilized
Shipping Conditions
The product is shipped at ambient temperature.
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM PB,150mM NaCl, pH7.4.
Species
Human
Shipping Temperature
Ambient
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog